Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

BTAI stock hub

BioXcel Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BTAIis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

33M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

BTAI

In the news

Latest news · BTAI

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC-265.5

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BTAI market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

197

Groups with data

Currency

USD

Showing 197 of 197 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001720893
Company name	BioXcel Therapeutics, Inc.
Country	United States
Country code	US
Cusip	09075P204
Employees	29
Employees Change	-8%
Employees Change Percent	-21.62
Enterprise value	$114.3M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2018-03-08
Isin	US09075P2048
Last refreshed	2026-05-10
Market cap	$33M
Market cap category	Nano-Cap
Price	$1.22
Price currency	USD
Rev Per Employee	22,137.93x
Sector	Healthcare
Sic	2834
Symbol	BTAI
Website	https://www.bioxceltherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-211.61%
EV Sales Forward	72.92x
EV/Sales	178x
FCF yield	-174.43%
P/S ratio	51.45x
PS Forward	21.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	74.45%
Gross Profit	$478,000
Gross Profit Growth	288.62%
Gross Profit Growth3 Y	10.42%
Net Income	$-69.9M
Net Income Growth Years	0%
Pretax Margin	-10,887.38%
Profit Per Employee	$-2.4M
ROA	-75.47
Roa5y	-59.33
ROCE	557.9
ROIC	-265.5

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-20.27%
Cagr3y	-85.12%
Cagr5y	-69.84%
EPS Growth Quarters	9
EPS Growth Years	2
Revenue Growth	-71.67x
Revenue Growth Q	-30.06x
Revenue Growth Years	0x
Revenue Growth3 Y	19.63x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.02
Assets	$44.9M
Cash	$28.4M
Current Assets	$44.7M
Current Liabilities	$53.9M
Debt	$109.7M
Equity	$-95.5M
Interest Coverage	-2.96
Liabilities	$140.4M
Long Term Assets	$231,000
Long Term Liabilities	$86.5M
Net Cash	$-81.2M
Net Cash By Market Cap	$-246
Tangible Book Value	$-95.5M
Tangible Book Value Per Share	$-4.28
WACC	10.79

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.83
Inventory Turnover	0.23
Net Working Capital	$-12.7M
Quick ratio	0.53
Working Capital	$-9.2M
Working Capital Turnover	$0.22

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-381.58%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-20.26%
200-day SMA	2.17
3Y total return	-99.67%
50-day SMA	1.32
50-day SMA vs 200-day SMA	50under200
5Y total return	-99.75%
All Time High	1,144
All Time High Change	-99.89%
All Time High Date	2020-07-20
All Time Low	1.01
All Time Low Change	20.79%
All Time Low Date	2026-04-13
ATR	0.1
Beta	0.31
Beta1y	3.88
Beta2y	2.22
Ch YTD	-23.75
High	1.26
High52	8.08
High52 Date	2025-08-12
High52ch	-84.9%
Low	1.19
Low52	1.01
Low52 Date	2026-04-14
Low52ch	20.79%
Ma50ch	-7.37%
Premarket Change Percent	-0.81
Premarket Price	$1.23
Premarket Volume	9,894
Price vs 200-day SMA	-43.78%
RSI	50.68
RSI Monthly	34.43
RSI Weekly	38.78
Sharpe ratio	0.41x
Sortino ratio	0.91
Total Return	-381.58%
Tr YTD	-23.75
Tr1m	11.93%
Tr1w	1.67%
Tr3m	-18.67%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	4
Analyst Count Top	1
Analyst Price Target Top	$4
Analyst Ratings	Strong Buy
Analyst Ratings Top	Hold
Earnings EPS Estimate	$-0.51
Earnings Revenue Estimate	363,192x
Earnings Revenue Estimate Growth	116.19x
Operating Income	$-50.3M
Operating margin	-7,829.8
Price target	$23
Price Target Change	$1,785
Price Target Change Top	$228

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	24,644,677%
Float Percent	91.03%
Shares Insiders	0.42%
Shares Institutions	7.48%
Shares Out	27,074,586
Shares Qo Q	53.96%
Shares Yo Y	381.58%
Short Float	16.01%
Short Ratio	3.99
Short Shares	14.58

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-60.4M
Average Volume	918,990.05x
Bv Per Share	-4.28
Ch1m	11.93
Ch1w	1.67
Ch1y	-20.26
Ch3m	-18.67
Ch3y	-99.67
Ch5y	-99.75
Ch6m	-33.33
Change	-1.61%
Change From Open	0
Close	1.24
Days Gap	-1.61
Depreciation Amortization	300,000
Dollar Volume	689,337.8
Earnings Date	2026-05-22
Earnings Time	bmo
EBIT	$-50.3M
EBITDA	$-50M
EPS	$-5.73
F Score	3
FCF	$-57.6M
FCF EV Yield	-50.42x
FCF Per Share	$-2.13
Financing CF	56,518,000
Fiscal Year End	December
Founded	2,017
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-27
Last Report Date	2025-12-31
Last Split Date	2025-02-10
Last Split Type	Reverse
Last10k Filing Date	2026-03-27
Ma150	1.72
Ma150ch	-29.07%
Ma20	1.15
Ma20ch	6.55%
Net CF	-1,097,000
Next Earnings Date	2026-05-22
Open	1.22
Optionable	No
Position In Range	42.86
Post Close	1.22
Postmarket Change Percent	-0.82
Postmarket Price	$1.21
Ppne	231,000
Pre Close	1.24
Price Date	2026-05-08
Relative Volume	0.61x
Revenue	642,000x
SBC By Revenue	431x
Share Based Comp	2,767,000
Tr6m	-33.33%
Us State	Connecticut
Volume	565,031
Z Score	-26.26

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does BTAI pay a dividend?

Capital-return profile for this ticker.

Performance

BTAI stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BTAI?

Insider, institutional, and short-interest positioning.

Institutional ownership

+7.5%

Float: +91.0% of shares outstanding

Insider ownership

+0.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

BTAI momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

50.7

Neutral momentum band

Price vs 200-day MA

-43.8%

50/200-day relationship not available

Beta (5Y)

0.31

Less volatile than the market

Sharpe ratio

0.41

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BTAI

Hub-level FAQ points readers to the deeper analysis pages.

What is the current BTAI stock rating?

BioXcel Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BTAI analysis?

The full report lives at /stocks/BTAI/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for BTAI?

The latest report frames BTAI around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the BTAI page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.